Caribou Biosciences, Inc. (CRBU) shareholders
Close on Nov 18, 2026Market cap $34.96MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,176,404 | 7.20% | 13G (passive) | Jun 30, 2026 |
| Rachel E. Haurwitz Joint filing with Felix Adler (5.00%) | 4,716,003 | 5.00% | 13D (active) | Apr 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRBU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,815,843 | 7.29% | $13.76M | +5,672,758 | 0.00% |
| Pfizer Inc | 4,690,431 | 4.38% | $7.88M | – | 4.63% |
| Vanguard Capital Management LLC | 4,208,568 | 3.93% | $7.41M | +441,340 | 0.00% |
| Mackenzie Financial Corp | 3,650,796 | 3.41% | $6.43M | +2,708,010 | 0.01% |
| Renaissance Technologies LLC | 2,773,545 | 2.59% | $4.88M | +183,048 | 0.01% |
| Kynam Capital Management, LP | 2,503,302 | 2.34% | $4.41M | – | 0.24% |
| Geode Capital Management, LLC | 2,374,894 | 2.22% | $4.18M | +1,356,935 | 0.00% |
| Acadian Asset Management LLC | 1,774,474 | 1.66% | $3.12M | +849,435 | 0.00% |
| State Street Corp | 1,632,914 | 1.52% | $2.87M | +1,209,651 | 0.00% |
| Bank Of America Corp /De/ | 1,410,958 | 1.32% | $2.48M | +113,791 | 0.00% |
| Two Sigma Investments, LP | 1,046,279 | 0.98% | $1.84M | −713,655 | 0.00% |
| Dimensional Fund Advisors LP | 975,327 | 0.91% | $1.72M | +302,127 | 0.00% |
| Charles Schwab Investment Management Inc | 775,809 | 0.72% | $1.37M | +216,167 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 764,820 | 0.71% | $1.35M | +217,806 | 0.00% |
| FMR LLC | 727,115 | 0.68% | $1.28M | +3,156 | 0.00% |
| Northern Trust Corp | 712,965 | 0.67% | $1.25M | +495,230 | 0.00% |
| Maverick Capital Ltd | 652,542 | 0.61% | $1.15M | – | 0.01% |
| Vanguard Portfolio Management LLC | 613,801 | 0.57% | $1.08M | New | 0.00% |
| Vanguard Fiduciary Trust Co | 606,388 | 0.57% | $1.07M | +86,270 | 0.00% |
| Qube Research & Technologies Ltd | 545,755 | 0.51% | $960.53K | +369,058 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 137 | 49M | 45.5% | 23 / 47 | 23 / 22 | 17M | 6M |
| Q1 2026 | 137 | 38M | 35.3% | 28 / 27 | 41 / 13 | 10M | 5M |
| Q4 2025 | 124 | 37M | 34.7% | 25 / 29 | 35 / 14 | 6M | 6M |
| Q3 2025 | 117 | 37M | 34.7% | 16 / 21 | 47 / 28 | 4M | 8M |
| Q2 2025 | 129 | 41M | 38.6% | 34 / 28 | 42 / 36 | 6M | 15M |
| Q1 2025 | 131 | 50M | 46.9% | 19 / 36 | 41 / 19 | 5M | 12M |
| Q4 2024 | 133 | 58M | 54.4% | 27 / 48 | 27 / 22 | 13M | 8M |
| Q3 2024 | 129 | 53M | 49.3% | 19 / 43 | 32 / 28 | 13M | 7M |
| Q2 2024 | 140 | 54M | 50.0% | 27 / 40 | 44 / 36 | 12M | 26M |
| Q1 2024 | 151 | 68M | 63.5% | 27 / 44 | 46 / 20 | 8M | 10M |
| Q4 2023 | 144 | 71M | 66.0% | 30 / 55 | 31 / 12 | 10M | 10M |
| Q3 2023 | 126 | 71M | 66.0% | 28 / 58 | 19 / 21 | 33M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
80 funds held CRBU in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRBU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,013,973 | 2.81% | $5.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,292,562 | 2.14% | $4.03M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,113,215 | 1.04% | $1.96M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 997,353 | 0.93% | $1.46M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 881,080 | 0.82% | $1.55M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 628,598 | 0.59% | $1.11M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 450,523 | 0.42% | $1.06M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 425,172 | 0.40% | $1.00M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 308,420 | 0.29% | $542.82K | 0.04% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 255,338 | 0.24% | $372.79K | 0.00% | Jul 31, 2026 |
| Bruce Fund | 250,000 | 0.23% | $440.00K | 0.12% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 223,613 | 0.21% | $326.47K | 0.00% | Jul 31, 2026 |
| AXS Green Alpha ETF | 201,851 | 0.19% | $355.26K | 0.62% | Jun 30, 2026 |
| Master Small Cap Index Series | 171,661 | 0.16% | $302.12K | 0.01% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 170,883 | 0.16% | $249.49K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rachel E. Haurwitz | President and CEO, Director | 3,816,545 | 3.56% | Feb 20, 2026 |
| Timothy P. Kelly | Chief Technology Officer | 73,125 | 0.07% | Feb 27, 2026 |
| Barbara G. McClung | Chief Legal Officer | 481,564 | 0.45% | Feb 24, 2026 |
| Tina M. Albertson | Chief Medical Officer | 68,523 | 0.06% | Feb 24, 2026 |
| Ruhi Ahmad Khan | Chief Business Officer | 104,998 | 0.10% | Feb 24, 2026 |
| Sriram Ryali | Chief Financial Officer | 72,360 | 0.07% | Feb 20, 2026 |
| Steven Kanner | Chief Scientific Officer | 431,556 | 0.40% | Feb 21, 2025 |
| Ryan Fischesser | VP of Finance and Controller | 118,854 | 0.11% | Nov 22, 2024 |
| Natalie Sacks | Director | – | – | Feb 20, 2026 |
| Ran Zheng | Director | – | – | Feb 20, 2026 |
| Nancy Whiting | Director | – | – | Feb 20, 2026 |
| Dara Richardson-Heron | Director | – | – | Feb 20, 2026 |
| Scott Braunstein | Director | – | – | Feb 20, 2026 |
| David Lee Johnson | Director | – | – | Feb 20, 2026 |
| Andrew Guggenhime | Director | – | – | Feb 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Timothy P. Kelly Chief Technology Officer | Feb 25, 2026 | Sale | −6,228 | $1.93 | $12.02K | 73,125 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −6,938 | $1.96 | $13.60K | 104,998 |
| Tina M. Albertson Chief Medical Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,066 | $1.96 | $2.09K | 68,523 |
| Barbara G. McClung Chief Legal Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −6,938 | $1.96 | $13.60K | 481,564 |
| Timothy P. Kelly Chief Technology Officer | Feb 24, 2026 | Sale | −3,147 | $1.96 | $6.17K | 79,353 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2026 | Award | +45,000 | – | – | 111,936 |
| Tina M. Albertson Chief Medical Officer | Feb 20, 2026 | Award | +55,000 | – | – | 69,589 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2026 | Award | +45,000 | – | – | 488,502 |
| Timothy P. Kelly Chief Technology Officer | Feb 20, 2026 | Award | +45,000 | – | – | 82,500 |
| Sriram Ryali Chief Financial Officer | Feb 20, 2026 | Award | +55,000 | – | – | 72,360 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2026 | Award | +151,700 | – | – | 447,150 |
| Rachel E. Haurwitz President and CEO, Director | Mar 14, 2025 | Buy | +20,000 | $1.02 | $20.40K | 3,369,395 |
| Steven Kanner Chief Scientific Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 431,556 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 66,936 |
| Barbara G. McClung Chief Legal Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 443,502 |
| Steven Kanner Chief Scientific Officer | Feb 20, 2025 | Award | +37,500 | – | – | 435,120 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2025 | Award | +37,500 | – | – | 70,500 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2025 | Award | +136,750 | – | – | 295,450 |
| Timothy P. Kelly Chief Technology Officer | Feb 20, 2025 | Award | +37,500 | – | – | 37,500 |
| Tina M. Albertson Chief Medical Officer | Feb 20, 2025 | Award | +14,589 | – | – | 14,589 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2025 | Award | +37,500 | – | – | 447,066 |
| Sriram Ryali Chief Financial Officer | Jan 29, 2025 | Buy | +17,360 | $1.42 | $24.65K | 17,360 |
| Ryan Fischesser VP of Finance and Controller | Nov 20, 2024 | Award | +25,000 | – | – | 118,854 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2024 | Award | +33,000 | – | – | 409,566 |
| Steven Kanner Chief Scientific Officer | Feb 20, 2024 | Award | +33,000 | – | – | 387,037 |
| Jason O'Byrne Chief Financial Officer | Feb 20, 2024 | Award | +33,000 | – | – | 59,224 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2024 | Award | +33,000 | – | – | 33,000 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2024 | Award | +118,700 | – | – | 158,700 |
| Steven Kanner Chief Scientific Officer | Feb 6, 2024 | Option exercise | +30,577 | $2.69 | $82.25K | 354,037 |
| Rachel E. Haurwitz President and CEO, Director | Jun 8, 2023 | Option exercise | +10,000 | $2.96 | $29.60K | 40,000 |
| Rachel E. Haurwitz President and CEO, Director | Mar 20, 2023 | Option exercise | +10,000 | $2.96 | $29.60K | 30,000 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Jan 19, 2023 | Sale | −5,627 | $6.31 | $35.51K | 59,373 |
| Steven Kanner Chief Scientific Officer | Dec 2, 2022 | Option exercise | +21,401 | $2.69 | $57.57K | 323,460 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Sale | −10,000 | $10.80 | $108.00K | 110,366 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Option exercise | +2,839 | $4.11 | $11.67K | 116,044 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Option exercise | +2,839 | $2.69 | $7.64K | 113,205 |
| Barbara G. McClung Chief Legal Officer | Sep 15, 2022 | Option exercise | +27,518 | $2.69 | $74.02K | 376,566 |
| Barbara G. McClung Chief Legal Officer | Sep 15, 2022 | Option exercise | +77 | $2.69 | $207 | 349,048 |
| Steven Kanner Chief Scientific Officer | Aug 25, 2022 | Option exercise | +43,248 | $2.69 | $116.34K | 345,307 |
| Steven Kanner Chief Scientific Officer | Aug 25, 2022 | Sale(10b5-1 plan) | −43,248 | $11.22 | $485.24K | 302,059 |
| Ryan Fischesser VP of Finance and Controller | Aug 22, 2022 | Award | +4,848 | – | – | 120,366 |
| Steven Kanner Chief Scientific Officer | May 13, 2022 | Option exercise | +68,306 | $1.81 | $123.63K | 295,945 |
| Steven Kanner Chief Scientific Officer | May 13, 2022 | Option exercise | +6,114 | $2.69 | $16.45K | 302,059 |
| Rachel E. Haurwitz President and CEO, Director | May 9, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 20,000 |
| Ryan Fischesser VP of Finance and Controller | May 5, 2022 | Option exercise | +1,136 | $2.69 | $3.06K | 114,380 |
| Ryan Fischesser VP of Finance and Controller | May 5, 2022 | Option exercise | +1,138 | $4.11 | $4.68K | 115,518 |
| Ryan Fischesser VP of Finance and Controller | Mar 15, 2022 | Option exercise | +1,138 | $4.11 | $4.68K | 113,244 |
| Ryan Fischesser VP of Finance and Controller | Mar 15, 2022 | Option exercise | +1,136 | $2.69 | $3.06K | 112,106 |
| Steven Kanner Chief Scientific Officer | Mar 4, 2022 | Option exercise | +1,549 | $4.11 | $6.37K | 227,639 |
| Steven Kanner Chief Scientific Officer | Mar 4, 2022 | Option exercise | +9,171 | $2.69 | $24.67K | 226,090 |
| Jason O'Byrne Chief Financial Officer | Feb 8, 2022 | Option exercise | +24,336 | $4.11 | $100.02K | 24,336 |
| Rachel E. Haurwitz President and CEO, Director | Jan 26, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 10,000 |
| Rachel E. Haurwitz President and CEO, Director | Jan 26, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 3,359,395 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Jan 25, 2022 | Award | +60,000 | – | – | 65,000 |
| Ryan Fischesser VP of Finance and Controller | Jan 11, 2022 | Buy | +569 | $2.69 | $1.53K | 102,264 |
| Ryan Fischesser VP of Finance and Controller | Jan 11, 2022 | Buy | +6,818 | $4.11 | $28.02K | 109,082 |
| Ryan Fischesser VP of Finance and Controller | Dec 20, 2021 | Buy | +1,136 | $2.69 | $3.06K | 101,695 |
| Barbara G. McClung Chief Legal Officer | Dec 7, 2021 | Buy | +6,115 | $2.69 | $16.45K | 348,971 |
| Barbara G. McClung Chief Legal Officer | Dec 7, 2021 | Buy | +12 | $2.69 | $32 | 342,856 |
| Barbara G. McClung Chief Legal Officer | Oct 20, 2021 | Buy | +9,176 | $2.69 | $24.68K | 342,801 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Caribou Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 76,175 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Timothy P. Kelly Officer | Feb 25, 2026 | 6,228 | $12.05K | Feb 25, 2026 | Restricted Stock |
| Barbara G. McClung Officer | Feb 25, 2026 | 6,938 | $13.60K | Feb 24, 2026 | Vesting of Restricted Stock Units |
| Ruhi Ahmad Khan Officer | Feb 25, 2026 | 6,938 | $13.60K | Feb 24, 2026 | Vesting of Restricted Stock Units |
See a number that looks wrong?